業績
武城 英明| 2013 | 2012 | 2011 | 2010 | 2009 | 2008 |
| 原著論文| 総説/著書| 国際会議| 国内会議 |
原著論文
Kuroda M‚ Bujo H‚ Aso M‚ Saito Y. Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases.
J. Diabet. Invest. 2011; 2 (5): 333-340
Asada A.‚ Kuroda M.‚ Aoyagi Y.‚ Bujo H.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Ishii I.‚ Aso M.‚ and Saito Y. Disturbed apolipoprotein A-I-containing lipoproteins in fish-eye disease are improved by the lecithin:cholesterol acyltransferase produced by gene-transduced adipocytes in vitro.
Mol. Genet. Metab. 2011; 102 (2): 229-231
Kuroda M.‚ Aoyagi Y.‚ Asada S.‚ Bujo H.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Ishii I.‚ Machida K.‚ Matsumoto F.‚ Satoh K.‚ Aso M.‚ and Saito Y. Ceiling culture-derived proliferative adipocytes are a possible delivery vehicle for enzyme replacement therapy in lecithin:cholesterol acyltransferase deficiency.
The Open Gene Ther. J. 2011; 4 1-10
Nakata Z.‚ Nagae M.‚ Yasui N.‚ Bujo H.‚ Nogi T.‚ and Takagi J. Crystallization and preliminary crystallographic analysis of human LR11 Vps10p domain.
Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun. 2011; 67 (Pt1): 129-132
Aoyagi Y.‚ Kuroda M.‚ Asada S.‚ Bujo H.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Ishii I.‚ Aso M.‚ and Saito Y. Fibrin glue increases the cell survival and the transduced gene product secretion of the ceiling culture-derived adipocytes transplanted in mice.
Exp. Mol. Med. 2011; 43 (3): 161-167
Asada S.‚ Kuroda M.‚ Aoyagi Y.‚ Fukaya Y.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Aso M.‚ Okamoto Y.‚ Nakayama T.‚ Saito Y.‚ and Bujo H. Ceiling culture-derived proliferative adipocytes retain high adipogenic potential suitable for use as a vehicle for gene transduction therapy.
Am. J. Physiol. Cell Physiol. 2011; 301 (1): C181-185
総説/著書
武城英明 non-HDLコレステロール ドクターサロン 2011; 55 6-9
武城英明 脂質異常症 ガイドライン外来診療2011 2011; 200-210
山崎健也‚ 田代 淳‚ 武城英明 大規模脂質介入試験Update Annual Review 糖尿病・代謝・内分泌 2011 2011; 146-155
Kuroda M.‚ Bujo H.‚ Aso M.‚ and Saito Y. Adipocytes as a vehicle for ex vivo gene therapy: Novel replacement therapy for diabetes and other metabolic diseases. J. Diabet. Invest. 2011; in press
国際会議
Kuroda M.‚ Asada S‚ Aoyagi Y.‚ Tanaka S.‚ Konno S.‚ Tanio M.‚ Aso M.‚ Saito Y.‚ and Bujo H. "Proliferative Adipocytes as Therapeutic Gene Vehicle toward Sustained Protein Replacement Therapy "
American Society of Gene & Cell Therapy 14th annual meeting 2011-6-23 Seattle/USA
Bujo H Circulating soluble LR11 -a novel molecule representing pathological immature cells-
Berlin Max-Delbrück-Center for Molecular Medicine symposium 2011-6-14 Berlin/Germany
Bujo H Circulating soluble LR11 -a novel molecule representing pathological immature cells-
Medical University of Vienna Biocenter Symposium 2011-6-13 Vienna/Austria
Bujo H Pharmacologic treatment for PAD in Japan – Cilostazol‚ and expected effects of lipid lowering drugs and probucol
1st Joint APSAVD-PLAS-PSVM Athersclerotic Prophrral Arterial Disease Forum 2011-5-22 Manila/Phillipine
Shimizu‚ N.‚ Nakaseko‚ C.‚ Takeuchi‚ M.‚ Ohwada‚ C.‚ Nishii‚ K.‚ Jiang‚ M.‚ Fukamachi‚ I. and Bujo‚ H. Soluble LR11‚ a modulator of G-CSF-mediated migration of HL-60 cells‚ is a potential circulating marker indicating the G-CSF-induced mobilization of hematopoietic stem cells.
Keystone Smmposia - Stem cells‚ cancer and metastasis- 2011-3-4 Kestone/USA
Bujo‚ H. LR11‚ a novel biomarker for cardiovascular diseases
Amsterdam University Academic Medical Center (AMC) Vascular Medicine Symposium 2011-3-2 Amsterdam/Holｌand
Shimizu N‚ Nakaseko C‚ Takeuchi M‚ Ohwada C‚ Tsukamoto S‚ Kawaguchi T‚ Nishii K‚ Jiang M‚ Yokote K‚ Fukamachi I‚ Bujo H Soluble LR11/SorLA‚ a potential circulating marker indicating the G-CSF-induced mobilization of hematopoietic stem cells‚ is a modulator of G-CDF-mediated migtration of HL-60 cells
The 53th American Society of Hematology 2011-12-9 San Diego/USA
Kawaguchi T‚ Ohwada C‚ Higashi M‚ Takeuchi M‚ Sakai S‚ Takeda Y‚ Shimizu N‚ Sakaida E‚ Takubo K‚ Ebinuma H‚ Fukamachi I‚ Tamaru J‚ Yokote K‚ Bujo H‚ Nakaseko C Serum soluble LR11 as a novel biomarker for B cell lymphoma
The 53th American Society of Hematology 2011-12-9 San Diego/USA
国内会議
武城英明、黒田正幸、麻生雅是 脂肪細胞移植の基礎と臨床応用
第65回日本栄養・食糧学会大会 2011-5-17 東京
武城英明 /新規病的細胞マーカー診断と脂肪細胞移植による遺伝子治療開発
第23回臨床検査診断治療懇話会 2011-2-3 千葉
Tsukamoto S‚ Takeuchi M‚ Sugita Y‚ Yamazaki A‚ Kawaguchi T‚ Sakai S‚ Takeda Y‚ Ohwada C‚ Sakaida E‚ Shimizu N‚ Nishii K‚ Jiang M‚ Yokote K‚ Bujo H‚ Nakaseko C Soluble LR11 activates THP-1 monocytes via interaction with CD87 and CD11b complex
第73回日本血液学会 2011-11-10 名古屋
深谷佳孝、黒田正幸、武城英明、窪田吉孝、秋田新介、力久直昭、三川信之、佐藤兼重 遺伝子導入前脂肪細胞による蛋白質欠損症の治療法開発に向けた移植細胞生着率向上に関する研究.
第20回日本形成外科学会基礎学術集会 2011-10-6 東京
Shimizu N‚ Nakaseko C‚ Sakai S‚ Tsukamoto S‚ Kawaguchi T‚ Takeda Y‚ Ohwada C‚ Takeuchi M‚ Sakaida E‚ Iseki T‚ Nishii K‚ Jiang M‚ Yokote K‚ Bujo H Soluble LR11 is a novel chemotaxis factor and enhances G-CSF-mediated migration of HL-60 cells
第73回日本血液学会 2011-10-10 名古屋
Kawaguchi T‚ Ohwada C‚ Sakai S‚ Takeda Y‚ Shimizu N‚ Takeuchi M‚ Sakaida E‚ Takubo K‚ Ebinuma H‚ Fukamachi I‚ Higashi M‚ Tamaru J‚ Yokote K‚ Bujo H‚ Nakaseko C Serum soluble LR11 is a promising novel biomarker for malignant lymphoma
第73回日本血液学会 2011-10-10 名古屋
武城英明 /肥満の臨床―病的脂肪細胞を標的とした治療―
第4回山形肥満治療エキスパートミーティング 2011-1-31 山形
